Piramal Pharma Solutions Targets European Biologics CDMO Growth

Piramal Pharma Solutions is moving to deepen its commercial presence in the European biologics outsourcing market, appointing Gregory Judge as Director to lead large-molecule partnership development across the region. The move positions the CDMO to compete more directly for biologics manufacturing contracts at a time when European pharma manufacturers are under pressure to secure reliable, GMP-compliant outsourcing partners for complex modalities.

In his new role, Judge will drive partnerships specifically for Piramal's large-scale molecule biologics business across Europe. For QA directors and supply chain leads evaluating CDMO partners, the appointment signals that Piramal is investing in dedicated regional business development capacity rather than managing European accounts from a centralized or remote function.

The European biologics CDMO market remains highly competitive, with manufacturers weighing factors including regulatory alignment with EMA expectations, process validation track records, and sterility assurance capabilities. A dedicated regional director with a mandate focused on large-molecule biologics suggests Piramal is prioritizing responsiveness and relationship depth with European clients as differentiating factors.

Source: This report is based on an announcement published by Media4Growth via Indian Pharma Post on April 27, 2026. Piramal Pharma Solutions has not issued additional technical or operational detail beyond the appointment and role scope at time of publication.